1. Academic Validation
  2. Small-Molecule Antagonists of the RIG-I Innate Immune Receptor

Small-Molecule Antagonists of the RIG-I Innate Immune Receptor

  • ACS Chem Biol. 2020 Feb 21;15(2):311-317. doi: 10.1021/acschembio.9b00810.
David C Rawling 1 G Erik Jagdmann Jr 2 Olga Potapova 2 Anna Marie Pyle 2 3
Affiliations

Affiliations

  • 1 Inflammatix, Inc , Burlingame , California 94010 , United States.
  • 2 Department of Molecular, Cellular and Developmental Biology , Yale University , New Haven , Connecticut 06520 , United States.
  • 3 Howard Hughes Medical Institute , New Haven , Connecticut 06520 , United States.
Abstract

The RIG-I receptor plays a key role in the vertebrate innate immune system, where it functions as a sensor for detecting Infection by RNA viruses. Although agonists of RIG-I show great potential as antitumor and antimicrobial therapies, antagonists of RIG-I remain undeveloped, despite the role of RIG-I hyperstimulation in a range of diseases, including COPD and autoimmune disorders. There is now a wealth of information on RIG-I structure, enzymatic function, and signaling mechanism that can drive new drug design strategies. Here, we used the enzymatic activity of RIG-I to develop assays for high-throughput screening, SAR, and downstream optimization of RIG-I antagonists. Using this approach, we have developed potent RIG-I antagonists that interact directly with the receptor and which inhibit RIG-I signaling and interferon response in living cells.

Figures
Products